logo
  

F5 Networks Q2 Profit Rises - Quick Facts

F5 Networks, Inc. (FFIV) reported second-quarter net income of $85.7 million or $1.18 per share, compared to $69.6 million or $0.91 per share, prior year. Adjusted earnings per share was $1.59, for the quarter.

On average, 36 analysts polled by Thomson Reuters expected the company to report profit per share of $1.50 for the quarter. Analysts' estimates typically exclude special items.

Revenue increased to $472.14 million from $420.04 million last year. Analysts expected revenue of $471.14 million for the quarter.

For the quarter ending June 30, 2015, the company has set a revenue goal of $475 million to $485 million with a GAAP earnings target of $1.16 to $1.19 per share and a non-GAAP earnings target of $1.57 to $1.60 per share. Analysts expect the company to report third-quarter earnings per share of $1.59 on revenue of $489.42 million.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
French drug major Sanofi reported Thursday weak profit in its first quarter, despite higher net sales. The company also maintained its fiscal 2024 outlook. Sanofi shares were gaining around 4 percent in Paris trading as well as in pre-market activity on the Nasdaq. While reporting financial results for the first quarter on Wednesday, medical devices company Boston Scientific Corp. (BSX) raised its adjusted earnings and net sales growth guidance for the full-year 2024. For fiscal 2024, the company now projects earnings in a range of $1.43 to $1.48 per share and... Shares of Roche Holding AG were losing around 3 percent in Switzerland after the drug major reported weak sales in its first quarter and confirmed fiscal 2024 outlook. Excluding COVID-19-related products, quarterly sales increasedy 7 percent. For fiscal 2024, Roche continues to expect an increase in group sales in the mid single digit range at constant exchange rates.

This week, we feature Nigeria’s combat with meningitis, Hostile takeover bid for Vanda Pharma, US opioid crisis, Sammy’s Milk’s safety concerns, and X4’s Mavorixafor’s fast-track status.

View More Videos
RELATED NEWS
Follow RTT